Cannabis-focused acquisition and investment firm RIV Capital Inc. RIV CNPOF reported on Monday its second-quarter financial results for the three months ended on June 30, 2023.
"A core focus of the business continues to be the thoughtful deployment of capital in New York, where we expect to benefit from a first-mover advantage in the wholesale market and aim to establish our position as a leading operator in the state," Eddie Lucarelli, the company's CFO, said. "Our liquidity position remains strong, and we anticipate executing on additional opportunities to further expand our geographical footprint with the core goal of driving sustained shareholder value."
New York cannabis market will undoubtedly be one of the hot topics at the upcoming Benzinga’s event in Chicago.
Q2 2023 Financial Highlights
- Revenue totaled $1.9 million, up from $1.4 million in the prior year's period.
- Gross profit totaled $393 000, down from $522 000 in the same quarter of 2022.
- Operating loss was $4.9 million, down from $5 million in the corresponding period of last year.
- Net loss amounted to $9.7 million, up from $3.5 million in the prior year's second quarter.
- Selling, general, and administrative expenses of $5.3 million compared to $5.5 million for the prior year's period.
- Cash at the end of the fiscal period was $90.7 million.
- As of June 30, the company had $258.3 million in total assets and $159.3 million in total liabilities.
Price Action
RIV Capital's shares traded 4.6512% higher at $0.09 per share at the time of writing on Tuesday morning.
The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.
Related News
- Riv Capital Stock Trading Higher On Stagnating Q3 FY23 Revenue And CEO Departing
- Riv Capital Settles With JW Asset Management, Repurchases Almost 20% Of Its Shares
- RIV Capital Q4 FY23 Revenue Declines 10.5% Hit By Illicit Market And Statewide Decline In Medical Cannabis Sales
Photo: Courtesy of geralt and Kindel Media by Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.